Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Ashlee D Brunaugh"'
Publikováno v:
PLoS ONE, Vol 16, Iss 2, p e0246803 (2021)
Niclosamide (NIC) has demonstrated promising in vitro antiviral efficacy against SARS-CoV-2, the causative agent of the COVID-19 pandemic. Though NIC is already FDA-approved, administration of the currently available oral formulation results in syste
Externí odkaz:
https://doaj.org/article/7b9a8a6ac8854a72a9191dcad8183f84
Autor:
Li Ding, Ashlee D. Brunaugh, Sven Stegemann, Scott V. Jermain, Matthew J. Herpin, Justin Kalafat, Hugh D. C. Smyth
Publikováno v:
Pharmaceutics, Vol 13, Iss 8, p 1213 (2021)
Capsule-based dry powder inhalers (cDPIs) are widely utilized in the delivery of pharmaceutical powders to the lungs. In these systems, the fundamental nature of the interactions between the drug/formulation powder, the capsules, the inhaler device,
Externí odkaz:
https://doaj.org/article/f96b50400fd64ad794997089c4e78a70
Publikováno v:
Journal of Pharmaceutical Sciences. 111:403-416
Monoclonal antibody (mAb) based therapies may provide a valuable new treatment modality for acute and chronic lung diseases, including asthma, respiratory infections, and lung cancer. Currently mAbs are delivered via systemic administration routes, b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67ab72374f525ff991d61618079a7ae8
https://doi.org/10.1016/j.xphs.2021.08.022
https://doi.org/10.1016/j.xphs.2021.08.022
Autor:
Ashlee D. Brunaugh, Amanda Walz, Zachary Warnken, Camron Pearce, Juan Munoz Gutierrez, John J. Koleng, Hugh D. C. Smyth, Mercedes Gonzalez-Juarrero
Publikováno v:
Antimicrob Agents Chemother
Tuberculosis (TB) remains a major cause of morbidity and mortality, particularly in low- and middle-income countries where access to health care workers, cold-chain storage, and sterile water sources may be limited. Inhaled drug delivery is a promisi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dae5f5172e3b5704328b39bc639a0dcf
https://doi.org/10.1128/aac.00186-22
https://doi.org/10.1128/aac.00186-22
Autor:
Li, Ding, Ashlee D, Brunaugh, Rishi, Thakkar, Christian, Lee, Qingyan Jenny, Zhao, Justin, Kalafat, Mohammed, Maniruzzaman, Hugh D C, Smyth
Publikováno v:
AAPS PharmSciTech
Despite the fact that capsules play an important role in many dry powder inhalation (DPI) systems, few studies have been conducted to investigate the capsules’ interactions with respirable powders. The effect of four commercially available hydroxyp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1529aa8d4a0386acf8d347dc6179582
https://doi.org/10.1208/s12249-021-02175-8
https://doi.org/10.1208/s12249-021-02175-8
Autor:
Ashlee D. Brunaugh, Li Ding, Sven Stegemann, Hugh D. C. Smyth, Matthew J. Herpin, Justin Kalafat, Scott V. Jermain
Publikováno v:
Pharmaceutics
Pharmaceutics, Vol 13, Iss 1213, p 1213 (2021)
Pharmaceutics, Vol 13, Iss 1213, p 1213 (2021)
Capsule-based dry powder inhalers (cDPIs) are widely utilized in the delivery of pharmaceutical powders to the lungs. In these systems, the fundamental nature of the interactions between the drug/formulation powder, the capsules, the inhaler device,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fbfc82ed819ed394cdb3d1ec1521024
http://europepmc.org/articles/PMC8399055
http://europepmc.org/articles/PMC8399055
Autor:
Hyojong Seo, Li Ding, Zachary N. Warnken, Ashlee D. Brunaugh, Hugh D. C. Smyth, Sang Heui Seo
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 2, p e0246803 (2021)
PLoS ONE, Vol 16, Iss 2, p e0246803 (2021)
Niclosamide (NIC) has demonstrated promising in vitro antiviral efficacy against SARS-CoV-2, the causative agent of the COVID-19 pandemic. Though NIC is already FDA-approved, administration of the currently available oral formulation results in syste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfdac07c87437a331bd9048dd012f31a
http://europepmc.org/articles/PMC7877651
http://europepmc.org/articles/PMC7877651
Autor:
Hyojong Seo, Hugh D. C. Smyth, Sang Heui Seo, Zachary N. Warnken, Ashlee D. Brunaugh, Li Ding
Niclosamide (NIC) has demonstrated promising in vitro antiviral efficacy against SARS-CoV-2, the causative agent of the COVID-19 pandemic. Though NIC is already FDA-approved, the oral formulation produces systemic drug levels that are too low to inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f18c99eb652d76cc6a03972948bf7b1
https://doi.org/10.1101/2020.09.24.310490
https://doi.org/10.1101/2020.09.24.310490
Publikováno v:
Molecular Pharmaceutics. 14:4019-4031
Clofazimine (CFZ) is highly active against mycobacterium, including resistant Mycobacterium tuberculosis, but its therapeutic efficacy via the oral route is limited by severe adverse effects, poor aqueous solubility, and slow onset of action. Pulmona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fc7d98d0fe3a25315f94e9921fb3918
https://doi.org/10.1021/acs.molpharmaceut.7b00690
https://doi.org/10.1021/acs.molpharmaceut.7b00690
Publikováno v:
Molecular pharmaceutics. 16(10)
Pulmonary delivery of biopharmaceuticals may enable targeted local therapeutic effect and noninvasive systemic administration. Dry powder inhaler (DPI) delivery is an established patient-friendly approach for delivering large molecules to the lungs;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55a842f419f85d3ab26da2f2a303b5a1
https://pubmed.ncbi.nlm.nih.gov/31448924
https://pubmed.ncbi.nlm.nih.gov/31448924